Investors & Media

Corporate Profile

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.

Investor Relations


Sara Blum Sherman
Senior Director
Investor Relations & Strategy
+1 212-271-0740
sara.sherman@dbv-technologies.com

Media Relations


Joe Becker
VP, Global Corporate Communications
+1 646-650-3912
joseph.becker@dbv-technologies.com

Subscribe
to get the latest
DBV press releases

Press Releases

DocumentYearTerms

12/06/2018 - 8:00 pm | Corporate | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

Download PDF (88 KB)

11/20/2018 - 7:30 am

DBV Technologies Presents Data at ACAAI 2018 on Investigational Viaskin Peanut for the Treatment of Peanut-Allergic Children

Download PDF (415 KB)

11/16/2018 - 7:30 am

DBV Technologies Appoints Daniel Tassé as Chief Executive Officer

Download PDF (451 KB)